Form 4: Longeveron CMO Awarded Significant Equity and Stock Options

Longeveron Inc.'s Chief Medical Officer, Nataliya Agafonova, was granted 102,000 Restricted Stock Units and 34,000 stock options, increasing her beneficial ownership.

Summary

• Nataliya Agafonova, Chief Medical Officer of Longeveron Inc. (LGVN), was the reporting person for this transaction.
• On July 15, 2025, Ms. Agafonova acquired 102,000 shares of Class A Common Stock in the form of time-based vesting Restricted Stock Units (RSUs).
• On the same date, she also acquired 34,000 stock options to purchase Class A Common Stock.
• The stock options have an exercise price of $1.47 per share and expire on July 15, 2035.
• The stock options will vest quarterly over a three-year period, commencing on October 1, 2025.
• Following these transactions, Ms. Agafonova beneficially owns 238,697 shares of Class A Common Stock, which includes RSUs subject to future vesting.
• She also beneficially owns 34,000 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of executive compensation, which is generally a neutral event. The grant of significant equity to a key executive can be seen as positive for aligning interests and retention, but it does not directly impact financial performance or operational news.

Positives

• The grant of significant equity (RSUs and stock options) to a key executive like the Chief Medical Officer aligns management's interests with long-term shareholder value.
• The multi-year vesting schedule for both RSUs and stock options indicates a commitment to retaining key talent and incentivizing long-term performance.

Future Outlook

The future vesting of the 102,000 Restricted Stock Units and the quarterly vesting of the 34,000 stock options over a three-year period starting October 1, 2025, represent future compensation events for the Chief Medical Officer.

Industry Context

Equity compensation, including Restricted Stock Units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key talent, particularly for critical roles such as Chief Medical Officers who are instrumental in product development and clinical trials.

Comparison to Industry Standards

• Granting significant equity to a Chief Medical Officer is a common practice in the biotech sector, aligning executive incentives with long-term company performance and shareholder value.
• Companies like Regeneron Pharmaceuticals, Inc. or Moderna, Inc. frequently utilize substantial equity awards to compensate and retain their top scientific and medical leadership, reflecting a similar strategy to Longeveron's approach in this filing.

Related Party Transactions

• The award of 102,000 Restricted Stock Units and 34,000 stock options to Nataliya Agafonova, the Chief Medical Officer, constitutes a related party transaction as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the Chief Medical Officer's interests with shareholder value through equity compensation, incentivizing long-term company performance.
• Employees: May signal stability and commitment from leadership, potentially boosting morale and confidence within the company.

Next Steps

• Future vesting of the 102,000 Restricted Stock Units.
• Quarterly vesting of the 34,000 stock options over a three-year period beginning October 1, 2025.

Key Dates

Keywords

Longeveron Inc., LGVN, SEC Form 4, Insider Trading, Stock Award, Restricted Stock Units, Stock Options, Chief Medical Officer, Equity Compensation, Beneficial Ownership